Genocea Biosciences Inc (NASDAQ:GNCA) Director George Siber bought 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 6th. The shares were purchased at an average cost of $0.61 per share, with a total value of $15,250.00. Following the purchase, the director now directly owns 27,017 shares of the company’s stock, valued at $16,480.37. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

George Siber also recently made the following trade(s):

  • On Tuesday, September 4th, George Siber bought 25,000 shares of Genocea Biosciences stock. The shares were purchased at an average cost of $0.62 per share, with a total value of $15,500.00.
  • On Friday, August 31st, George Siber bought 25,000 shares of Genocea Biosciences stock. The shares were purchased at an average cost of $0.61 per share, with a total value of $15,250.00.
  • On Wednesday, August 29th, George Siber bought 25,000 shares of Genocea Biosciences stock. The shares were purchased at an average cost of $0.61 per share, with a total value of $15,250.00.

Shares of NASDAQ GNCA opened at $0.82 on Thursday. Genocea Biosciences Inc has a 12 month low of $0.49 and a 12 month high of $2.15. The firm has a market cap of $62.13 million, a PE ratio of -0.41 and a beta of 1.03. The company has a debt-to-equity ratio of 0.95, a current ratio of 6.84 and a quick ratio of 6.84.

Genocea Biosciences (NASDAQ:GNCA) last announced its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02. research analysts anticipate that Genocea Biosciences Inc will post -0.47 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in GNCA. California State Teachers Retirement System lifted its holdings in shares of Genocea Biosciences by 166.6% during the first quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 78,469 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of Genocea Biosciences during the fourth quarter valued at $145,000. LMR Partners LLP purchased a new stake in shares of Genocea Biosciences during the second quarter valued at $175,000. Schwab Charles Investment Management Inc. purchased a new stake in shares of Genocea Biosciences during the first quarter valued at $177,000. Finally, DRW Securities LLC purchased a new stake in shares of Genocea Biosciences during the second quarter valued at $205,000. 60.23% of the stock is owned by institutional investors and hedge funds.

GNCA has been the subject of several research reports. ValuEngine raised Genocea Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Zacks Investment Research downgraded Genocea Biosciences from a “hold” rating to a “sell” rating in a report on Wednesday, July 11th. Finally, HC Wainwright set a $5.00 target price on Genocea Biosciences and gave the company a “buy” rating in a report on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $3.79.

About Genocea Biosciences

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Read More: Price to Earnings Ratio (PE), For Valuing Stocks

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.